Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
/in Dendritic Cells, International Publications, Malignant Melanoma, Malignant Pleural Mesothelioma /von 2021-05-19 / Vaccines (Basel) 2021 May;9(5)Oncolytic Viral Therapy for Malignant Pleural Mesothelioma
/in International Publications, Malignant Pleural Mesothelioma, Newcastle Disease Virus /von 2020-07-01 / J Thorac Oncol 2020 Jul;15(7):e111-e113Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-12 / Front Oncol 2020;10:343T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-01 / J Immunother Cancer 2020 Mar;8(1)Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-27 / Cancers (Basel) 2020 Feb;12(3)Immunotherapy in Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-21 / Front Oncol 2020;10:187Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma, Newcastle Disease Virus /von 2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S119Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2019-05-14 / BMJ Open 2019 05;9(5):e026779Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2018-09-07 / Front Immunol 2018;9:2034
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives